PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.8533
+0.0201 (2.41%)
Jan 5, 2026, 4:00 PM EST - Market closed
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,453,539
Market Cap
46.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 27 days ago - PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - GlobeNewsWire
- 4 weeks ago - PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) - GlobeNewsWire
- 7 weeks ago - PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 7 weeks ago - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 - GlobeNewsWire
- 2 months ago - PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire